Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 25 April 2012 | By Alexander Gaffney, RAC
An analysis of US Food and Drug Administration (FDA) warning letters issued in 2011 shows the majority of all facilities receiving a warning letter were deficient in areas relating to batch failure investigation, reports In-Pharma Technologist.
"In the manufacturing-related warning letters analyzed by in-Pharma Technologist, FDA made 211 numbered observations," of which 10% were related to the company not investigating batch failures.
Despite only 10% of all observations being about batch failures, almost half of all facilities receiving a warning letter were cited for "failure to thoroughly investigate batch failure," notes in-Pharma Technologist.
In-Pharma Technologist's analysisalso noted that an additional third of all companies receiving warning letters were warned after FDA found they did not have written procedures to ensure quality.
In-Pharma Technologist - Half of FY11 FDA GMP warning letters tied to batch failures
Tags: Written Procedures, Batch Failure, QA, QC, Latest News, warning letters, regulatory